These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 34476174)

  • 1. The Metabolic Features of Tumor-Associated Macrophages: Opportunities for Immunotherapy?
    Mojsilovic SS; Mojsilovic S; Villar VH; Santibanez JF
    Anal Cell Pathol (Amst); 2021; 2021():5523055. PubMed ID: 34476174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy.
    Chen S; Lai SWT; Brown CE; Feng M
    Front Immunol; 2021; 12():635173. PubMed ID: 33790906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manipulating macrophage polarization in cancer patients: From nanoparticles to human chimeric antigen receptor macrophages.
    Santoni M; Massari F; Montironi R; Battelli N
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188547. PubMed ID: 33932561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T-cell therapy for solid tumours.
    The Lancet Oncology
    Lancet Oncol; 2021 Jul; 22(7):893. PubMed ID: 34197740
    [No Abstract]   [Full Text] [Related]  

  • 5. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
    Sloas C; Gill S; Klichinsky M
    Front Immunol; 2021; 12():783305. PubMed ID: 34899748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting tumor-associated macrophages as an antitumor strategy.
    Cheng N; Bai X; Shu Y; Ahmad O; Shen P
    Biochem Pharmacol; 2021 Jan; 183():114354. PubMed ID: 33279498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy.
    Rodriguez-Garcia A; Lynn RC; Poussin M; Eiva MA; Shaw LC; O'Connor RS; Minutolo NG; Casado-Medrano V; Lopez G; Matsuyama T; Powell DJ
    Nat Commun; 2021 Feb; 12(1):877. PubMed ID: 33563975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies.
    Dong Y; Wan Z; Gao X; Yang G; Liu L
    Front Immunol; 2021; 12():609762. PubMed ID: 33968014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy.
    Fan C; Zhang S; Gong Z; Li X; Xiang B; Deng H; Zhou M; Li G; Li Y; Xiong W; Zeng Z; Li X
    Sci China Life Sci; 2021 Apr; 64(4):534-547. PubMed ID: 32815067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment.
    Nachef M; Ali AK; Almutairi SM; Lee SH
    Front Immunol; 2021; 12():624324. PubMed ID: 33953707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
    Miao L; Zhang Z; Ren Z; Tang F; Li Y
    Front Immunol; 2021; 12():687822. PubMed ID: 34093592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.
    Waibl Polania J; Lerner EC; Wilkinson DS; Hoyt-Miggelbrink A; Fecci PE
    Front Immunol; 2021; 12():777073. PubMed ID: 34868044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy.
    Zhang SY; Song XY; Li Y; Ye LL; Zhou Q; Yang WB
    Pharmacol Res; 2020 Nov; 161():105111. PubMed ID: 33065284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Nanoimmunotherapy by Modulating Tumor-Associated Macrophages for Cancer Therapy.
    Hao J; Zhao X; Wang C; Cao X; Liu Y
    Bioconjug Chem; 2024 Jul; 35(7):867-882. PubMed ID: 38919067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy.
    Li YR; Yu Y; Kramer A; Hon R; Wilson M; Brown J; Yang L
    Cells; 2022 May; 11(9):. PubMed ID: 35563889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting tumor-associated macrophages to synergize tumor immunotherapy.
    Xiang X; Wang J; Lu D; Xu X
    Signal Transduct Target Ther; 2021 Feb; 6(1):75. PubMed ID: 33619259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches.
    Klein K; He K; Younes AI; Barsoumian HB; Chen D; Ozgen T; Mosaffa S; Patel RR; Gu M; Novaes J; Narayanan A; Cortez MA; Welsh JW
    Front Immunol; 2020; 11():573326. PubMed ID: 33178201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism in tumour-associated macrophages: a
    Zheng X; Mansouri S; Krager A; Grimminger F; Seeger W; Pullamsetti SS; Wheelock CE; Savai R
    Eur Respir Rev; 2020 Sep; 29(157):. PubMed ID: 33004525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Antigen Presentation in Tumor-Associated Macrophages.
    Stopforth RJ; Ward ES
    Crit Rev Immunol; 2020; 40(3):205-224. PubMed ID: 33389885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SHISA3 Reprograms Tumor-Associated Macrophages Toward an Antitumoral Phenotype and Enhances Cancer Immunotherapy.
    Zhang S; Yu B; Sheng C; Yao C; Liu Y; Wang J; Zeng Q; Mao Y; Bei J; Zhu B; Chen S
    Adv Sci (Weinh); 2024 Sep; 11(36):e2403019. PubMed ID: 39054639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.